The FDA extended the duration of use of Nexplanon for pregnancy prevention in women of reproductive potential for up to 5 years.
Medical Device Network on MSN
FDA expands use of Organon’s contraception implant up to 5 years
Organon’s Nexplanon can now be implanted for up to five years after the FDA approved a supplemental New Drug Application by the company.
Organon & Co. OGN recently announced that the FDA has approved a supplemental New Drug Application, extending the duration of use of NEXPLANON (etonogestrel implant) 68 mg Radiopaque to up to five ...
The U.S. Food and Drug Administration (FDA) has approved a label expansion for Nexplanon to allow its manufacturer, Organon (OGN), to market the birth control implant, indicating an efficacy duration ...
JERSEY CITY, N.J.--(BUSINESS WIRE)-- Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today that the US ...
A Cochrane Systematic Review that set out to assess the effectiveness and tolerability of subdermal implantable contraceptives compared to other reversible methods of contraception found that they ...
Organon Announces US Food and Drug Administration Approval of Supplemental New Drug Application Extending Duration of Use of NEXPLANON® (etonogestrel implant) 68 mg Radiopaque Organon (NYSE: OGN), a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results